Page 22 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

17. Montero, A. J., Eapen, S., Gorin, B. & Adler, P. The economic burden of metastatic breast cancer: a U.S. managed
care perspective. Breast Cancer Res Treat. 2012; 134(2), 815–22.
18. Broekx, S., Den Hond, E., Torfs, R., Remacle, A., Mertens, R., D'Hooghe, T., Neven, P., Christiaens, M. R. &Simoens,
S. The costs of breast cancer prior to and following diagnosis. Eur J Health Econ. 2011; 12(4), 311–7.
19. Blumen, H., Fitch, K. &Polkus, V. Comparison of treatment costs for breast cancer, by tumor stage and type of
service. Am Health Drug Benefits. 2016; 9(1), 23–32.
20. Gordon, L., Scuffham, P., Hayes, S. & Newman, B. Exploring the economic impact of breast cancers during the
18 months following diagnosis. Psychooncology, 2007; 16(12), 1130–9.
21. Lidgren, M., Wilking, N., Jonsson, B. &Rehnberg, C. Health related quality of life in different states of breast
cancer. Qual Life Res. 2007b; 16(6), 1073–81.
22. Lamerato, L., Havstad, S., Gandhi, S., Jones, D. & Nathanson, D. Economic burden associated with breast cancer
recurrence: findings from a retrospective analysis of health system data. Cancer. 2006; 106(9), 1875-82.
23. Masaquel, C., Hurley, D., Barnett, B., Krieger, T., Pearson, I., Copley-Merriman, C., Kaye, J. A. & Moy, B. Clinical and
Economic Burden of HER2-Positive Breast Cancer Recurrence in the US: A Literature Review. Poster presented
at the 2017 San Antonio Breast Cancer Symposium. 2017. San Antonio, TX.
24. Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA. Health care costs for the treatment of breast cancer
recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer. 2007;97(4):479-485.
doi:10.1038/sj.bjc.6603887
25. Park JH, Lee SK, Lee JE, Kim SW, Nam SJ, Kim JY, Ahn JS, Park W, Yu J, Park YH. Breast Cancer
Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean
Economy. J Breast Cancer. 2018 Mar;21(1):91-95.
26. Yin, W., Horblyuk, R., Perkins, J. J., Sison, S., Smith, G., Snider, J. T., Wu, Y. & Philipson, T. J. Association between
breast cancer disease progression and workplace productivity in the United States. J Occup Environ Med. 2017;
59(2), 198–204.
27. Yin, W., Horblyuk, R., Perkins, J. J., Sison, S., Smith, G., Thornton-Snider, J., Wu, Y. & Philipson, T. J. Breast cancer
progression and workplace productivity. Journal of Clinical Oncology. 2015; 33(15_suppl.), 6586.
28. Von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A.,
Rouchet, N., Clark, E., et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N
Engl J Med. 2017; 377(2), 122–31.
29. Schneeweiss A, et al. Ann Oncol. 2013; 24:2278–2284
30. Swain, S. M., Ewer, M. S., Viale, G., Delaloge, S., Ferrero, J. M., Verrill, M., Colomer, R., Vieira, C., Werner, T. L.,
Douthwaite, H., et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based
chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer
(BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018; 29(3),
646-653.
31. Loibl S, et al. Ann Oncol. 2017; 28:497–504
32. Hurvitz SA, et al. Lancet Oncol. 2018; 19:115–126
33. Baselga J, Cortés J, Kim S-B, et al; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for
metastatic breast cancer. N Engl J Med. 2012;366(2):109-119.
34. Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A.,
Knott, A., et al. (2013). Pertuzumab, trastuzumab
35. PERJETA. Local UAE PI
36. Herceptin. Local UAE PI

M-AE-00000086 22